Research programme: sodium channel antagonists - Vernalis

Drug Profile

Research programme: sodium channel antagonists - Vernalis

Latest Information Update: 16 Aug 2010

Price : $50

At a glance

  • Originator Vernalis
  • Class
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Neuropathic pain
  • No development reported CNS disorders; Stroke

Most Recent Events

  • 05 Oct 2004 This programme is still in active development for CNS disorders
  • 03 Oct 2003 Vernalis Group has merged with British Biotech to form Vernalis
  • 27 Jun 2002 Discontinued - Preclinical for Stroke in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top